Public Companies
FDA Issues Warning Letter for Ketamine
The FDA has issued a warning letter regarding the use of ketamine outside of FDA-approved conditions.
The post FDA Issues Warning Letter for Ketamine…
The FDA has issued a warning letter regarding the use of ketamine outside of FDA-approved conditions. This notice seems to be in response to the growing use of ketamine for the treatment of mental health conditions.
With the increased and un-regulated use of ketamine to treat mental health conditions (outside of ketamine’s original FDA approval) there have been growing concerns of misuse, abuse, and other potential dangers — the likely motivation behind this letter.
The FDA is generally supportive of ketamine development, so this warning shouldn’t be taken as a sign of the FDA growing sour on ketamine. For example, PharmaTher has recently received 5 different FDA orphan drug designations for its ketamine developments.
With ketamine increasing in medical and recreational use, this letter is a good opportunity to review some of the basics of ketamine in both its FDA-approved and “off-label” use. Here are some highlights from the FDA’s notice with additional context (some points taken directly from the letter):
- Ketamine is a Schedule III controlled substance FDA-approved as an intravenous or intramuscular injection for general anesthesia.
- Ketamine is not FDA approved for the treatment of psychiatric disorders. Despite it being used “off-label” for mental health conditions, the FDA has not approved ketamine as safe and effective for such uses.
- Ketamine products used by clinics and telehealth providers are “compounded” ketamine, not the FDA-approved version of the drug.
- Drug compounding is the process of combining, mixing, or altering approved ingredients to create a tailored medication. In some cases, they can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug product.
- Compounded drugs, including compounded ketamine products, are not FDA-approved, which means the FDA has not evaluated their safety, effectiveness, or quality prior to marketing.
- Use of compounded ketamine products without monitoring by a health care provider for sedation (sleepiness), dissociation (disconnection between a person’s thoughts, feelings, and sense of space, time, and self), and changes in vital signs (such as blood pressure and heart rate) may put patients at risk for serious adverse events.
- Spravato (which includes only the esketamine molecule), is the only FDA-approved ketamine product for mental health conditions; a nasal spray for treatment-resistant depression in adults with major depressive disorder with acute suicidal ideation (in conjunction with an oral antidepressant).
For more on ketamine’s increased use and potential issues, check out A Deeper Look at Ketamine and its Potential for Addiction
The post FDA Issues Warning Letter for Ketamine appeared first on Microdose.
ketamine major depressive disorder depressive disorder depression antidepressant pharmather fda-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update